ELEVATE IPF Phase 2b Open-Label Extension with Deupirfenidone. ERS Congress. 2025. Tzouvelekis A, et al. [Oral Presentation]
Previous
Previous
PureTech Presents New Data from Phase 2b Open-Label Extension Study of Deupirfenidone (LYT-100), Further Supporting Strong and Durable Efficacy and Potential to Serve as New Standard of Care in IPF
Next
Next